114 results about "DNA methyltransferase" patented technology

Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.

Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders.

The invention relates to the inhibition of DNA methyltransferase isoforms DNMT1 and DNMT3b2. The invention provides compounds and methods for inhibiting DNMT1 and DNMT3b2.

The invention discloses a nanosensor for detecting DNA methyltransferase based on a single quantum dot. The nanosensor only comprises a single detection probe thereby preventing complex detection design and cumbersome signal amplification steps. The nanosensor has high selectivity and high sensitivity to DNA methyltransferase. The nanosensor comprises a tail end 3'-biotinylated hairpin detection probe. The tail end 5' of the detection probe is labeled with a fluorophore cyanine 5(Cy5). The tail end 3' is labeled with a quenching group black hole quenching agent (BHQ2). The stem region contains a recognition sequence 5'-GATC-3' of a target DNA methyltransferase. The surface is coated with a streptavidin quantum dot. Through interaction of streptavidin and biotin, the probe is connected to the streptavidin-modified quantum dot surface so that a quantum dot/probe/cyanine 5/black hole quenching agent complex is formed. The nanosensor also comprises a methylation-specific endonuclease (DpnI).

Biomarkers for diagnosis and prognosis of prostate cancer are provided. The biomarkers are promoter sequences have altered methylation patterns relative to normal prostate tissue. Altered expression of DNA methyltransferases (DNMT) and proteins that interact with DNMT result in increased methylation at a subset of prostate tumor hypermethylation sites.

Provided is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule encoding the Bmi1 protein; and b) at least one low molecular weight substance selected from the group consisting of a set of a MEK/ERK (mitogen-activated protein kinase/extracellular regulated kinase) inhibitor and a GSK (glycogen synthase kinase) inhibitor, a set of a G9a HMTase (G9a histone methyltransferase) inhibitor and a DMNT (DNA methyltransferase) inhibitor, and a histone deacetylase inhibitor. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the reprogramming factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.

The invention provides a Taqman fluorescent hydrolysis probe and a method for quantitatively detecting the methylation level of MGMT (O6-methylguanine-DNA-methyltransferase) by using the Taqman hydrolysis probe. The fundamental sequence of the Taqman fluorescent hydrolysis probe is GATTTGGTGAGTGTUTGGG, and the complementary region of the fundamental sequence and a genomic DNA (deoxyribonucleic acid) sequence extends upstream no more than 5nt and extends downstream no more than 5nt. According to the invention, the specificity of PCR (polymerase chain reaction) is doubly guaranteed; the percent of a methylated DNA template in a mixed sample can be quantitatively calculated; and the method has all the advantages (such as speediness, sensitiveness, no pollution, and the like) of the real-time quantitative PCR. The application of detection results of the invention can provide clinical guide for medicaments for carrying out chemotherapy on malignant tumors such as cerebral gliomas and the like; and the method has the advantages of high specificity, high sensitivity, accurate quantification, and the like.

Compounds represented by Formula (I):

are useful in treating diseases, such as cancer, that are mediated and/or associated (at least in part) with DNMT3b activity. The compounds can be formulated as pharmaceutically acceptable compositions for administration to a subject in need thereof.

The virulence of bacterial strains and in particular pathogenic bacteria which infect human is reduced by an agent which alters the bacteria's native level or activity of DNA methyltransferase (Dam). The agent causes an alteration in the bacteria's native level of methylation of adenine in a GATC tetranucleotide which inhibits virulence of the bacteria. Thus, compounds and formulations thereof which reduce bacterial virulence inhibit proliferation of bacteria and are useful in treating bacterial infections, particularly in humans.

The invention provides a chemiluminescent test kit for testing activity of MGMT (O6-Methylguanine DNA-Methyltransferase), which comprises a streptavidin magnetic bead, a biotinylated O6-benzyl guanine, an enzyme label for MGMT specific antibody anti-MGMT, a standard substance solution of the MGMT, a luminescent substrate fluid and a concentrated cleaning solution. The invention also discloses a test method for applying the test kit to MGMT. The test method comprises the following steps: firstly, extracting total protein from a sample; testing by using the test kit; and lastly analyzing a test result. The invention provides the chemiluminescent test kit and the test method for testing the activity of MGMT in human tissues or cells; the chemiluminescent test kit and the test method have the advantages of convenience and high speed in operation, high flexibility of test result, strong specificity, and the like; and the chemiluminescent test kit and the test method have wide application prospects in the aspect of clinical test for the activity of MGMT.

The present invention provides isolated nucleic acids encoding delta DNA methyltransferase 3B molecules that are involved in the treatment and prevention of cancers such as, but not limited to, lung cancer. The delta DNA methyltransferase 3B molecules of the present invention are found to play a critical role in promoter-specific methylation of tumor suppressor genes. The DNA methyltransferase 3B molecules of the present invention are provided as therapeutic targets for identifying inhibitors of DNA methyltransferase. Such inhibitors are contemplated for the treatment and/or prevention of cancers. In particular embodiments, the present invention involves the treatment and prevention of a non-small cell lung cancer.

The invention discloses a small molecule compound combination and a method for preparing vascular endothelial cells by using the small molecule compound combination to induce differentiated cells. According to the method, differentiated cells are subjected to targeted induction so as to finally obtain vascular endothelial cells, wherein the targeted induction comprises: inhibiting the activity oflysine deacetylase activity, inhibiting the signaling pathway of TGF-beta, inhibiting the activity of DNA methyltransferase (DNMT), activating the signaling pathway of WNT/beta-catenin, and activatingthe signaling pathway of cAMP. According to the present invention, through the induction with the small molecule compound combination, the differentiated cells can be transdifferentiated into the vascular endothelial cells, each step can be subjected to precise quality control, and the standardized operation and the large-scale production can be conveniently achieved; and the donor source of themethod is wide, the patient himself can be served as the donor, and the vascular endothelial cells required by basic research, clinical treatment or tissue engineering production can be obtained within a short time.

The invention provides a sensor based on TdT-RCA and application thereof in DNA methyltransferase detection, the sensor comprises a Dam methyltransferase detection probe and a dumbbell-shaped rollingring template. According to the sensor based on TdT-RCA and application thereof in DNA methyltransferase detection, the non-specific amplification of terminal transferase (TdT) activation is effectively prevented by carrying out amination modification on the 3' end of a substrate hairpin probe acting on methyltransferase, so that a background signal is reduced, and the specificity of the detectionmethod is greatly improved; the primer extension catalyzed by TdT is combined with a dumbbell-shaped template-mediated rolling circle amplification (RCA) reaction, thionein T (ThT) is taken as fluorescent dye (thionein T is specifically combined with a reaction product G triple chain as a signal output), the fluorescent label is not needed, the operation is simple, and the experimental cost is reduced; the method can better distinguish the Dam methyltransferase from other methyltransferase and has better selectivity.

karounitriol is an important active ingredient from traditional Chinese medicine material semen trichosanthis. The invention discloses a novel function of karounitriol. It is found through experiments of the action of semen trichosanthis glycol on rat primary culture nerve cells that the expression level of DNMT1 genes can be reduced by addition of karounitriol. DNMT1 is the key enzyme causing DNA methylation which is an important constituent part of epigenetics, changes of DNA methylation represent that the nervous system makes a global stress reaction on karounitriol, and it is shown that karounitriol has a significant regulating effect on activities of the nervous system.

This invention relates to heteroaryl compounds, containing a purinyl moiety, that inhibit DNA methyltransferase (DNMT) activity—including DNMT1, DNMT3a, or DNMT3b—useful in the treatment of cancer and hyperproliferative diseases.

The present invention relates to a monoclonal antibody of specific conjugated O6-methylguanine-DNA methyltransferase KRTTLDSPLGKLE(C) sequence and hybridoma cell line CGMCC 0827 capable of secreting said monoclonal antibody. Said invention also relates to the method for preparing said monoclonal antibody and the application of the described monoclonal antibody in preparation of horizontal detection kit for identifying O6-methylguarine-DNA methyltransferase in the sample. Said invention also relates to the method for utilizing said kit.

The invention belongs to the field of gene therapy and relates to preparation and an application of an expression vector for targeted inhibition of HIV-1 provirus expression by use of embedded DNA methyltransferase adopting a zinc finger structure. The expression vector carrying the DNA methyltransferase adopting the zinc finger structure is proved to be able to inhibit silence of HIV-1 provirus expression in HIV-1 infection and latent infection cell models, the vector can effectively inhibit virus replication in virus infected cells and latent infected cells for 15-40 days or above. Besides,provirus expression silence caused by the expression vector carrying the embedded methyltransferase adopting the zinc finger structure can be inhered among cell generations and has certain safety in cells. A new idea is provided for curing AIDS.

The invention discloses a method for detecting the activity of O6-methylguanine-DNA (Deoxyribose Necleic Acid) methyltransferase. The method is that the activity of O6-methylguanine-DNA (Deoxyribose Necleic Acid) methyltransferase is detected by adopting a bioluminescence resonance energy transfer technology and a chemiluminescence technology for the first time, and comprises the steps of incubating streptavidin-luciferase fusion protein and O6-methylguanine-DNA methyltransferase labeled by biotin for 30-60 minutes at the temperature of 0-40 DEG C, then adding O6-methylguanine-DNA methyltransferase antibody labeled by fluorochrome, incubating for 30-60 minutes at the temperature of 0-40 DEG C, then adding a fluorescein substrate, standing for 5-30 minutes at the temperature of 4-30 DEG C, detecting the lighting intensity at the position of 670nm, and further calculating to obtain the activity of O6-methylguanine-DNA methyltransferase. According to the method disclosed by the invention, the operation is simple and convenient, the applicable range is wide, the scattering caused by exogenous exciting light and the interference of backgrounds such as sample matrix fluorescence can be avoided, and the sensitivity and the accuracy are high.

The present disclosure is directed to compositions and methods for treating osteoarthritis comprising increasing the expression of Dnmt3b and/or inhibiting aminobutyrate aminotransferase.

A method for labeling unmethylated CpG dinucleotides within a DNA fragment, and use of the method in profiling of genomic DNA methylation. The present invention further provides modified DNA methyltransferase enzymes and compounds which are capable of being used by the enzymes as cofactors for use in the labeling method.

The invention discloses a method for constructing a eukaryotic expression plasmid containing a human O6-methylguanine-DNA methyltransferase (MGMT) gene and application of the eukaryotic expression plasmid to the research of drug-resistant genes. The method concretely comprises the following steps: RT-PCR is utilized to obtain cDNA of an MGMT gene from a human liver tissue, and the cDNA is cloned into a T vector and performs restriction enzyme recombination with the eukaryotic expression plasmid containing enhanced fluorescent protein to construct the eukaryotic expression plasmid containing the human MGMT gene. The eukaryotic expression plasmid containing the human MGMT gene is transfected into a K562 cell and is subjected to pressure selection to construct a steady K562/MGMT transfection cell system. The invention also comprises application of the plasmid to the change of the drug resistance of tumor cells and normal cells. The method for constructing the plasmid is based on the prior experimental conditions of cell and molecular biology, does not need large-scale and complicated experimental facilities, has simple and convenient operation, and is safe and high-efficiency. The constructed plasmid has good physical and chemical stability, is easy to detect after the plasmid is transfected into the cell, and has high abundance expression. The method provides new experimental resources and means for MGMT-related research of the drug-resistant genes as well as gene treatment and research of tumor, and is worthy to be promoted and applied.